经病理证实的阿尔茨海默病和额颞叶痴呆的神经心理学测试:统一数据集测量在区分疾病方面的效果如何?

Neuropsychological Testing in Pathologically Verified Alzheimer Disease and Frontotemporal Dementia: How Well Do the Uniform Data Set Measures Differentiate Between Diseases?

作者信息

Ritter Aaron R, Leger Gabriel C, Miller Justin B, Banks Sarah J

机构信息

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV.

出版信息

Alzheimer Dis Assoc Disord. 2017 Jul-Sep;31(3):187-191. doi: 10.1097/WAD.0000000000000181.

Abstract

BACKGROUND/AIMS: Differences in cognition between frontotemporal dementia (FTD) and Alzheimer disease (AD) are well described in clinical cohorts, but have rarely been confirmed in studies with pathologic verification. For emerging therapeutics to succeed, determining underlying pathology early in the disease course is increasingly important. Neuropsychological evaluation is an important component of the diagnostic workup for AD and FTD. Patients with FTD are thought to have greater deficits in language and executive function while patients with AD are more likely to have deficits in memory.

OBJECTIVES

To determine if performance on initial cognitive testing can reliably distinguish between patients with frontotemporal lobar degeneration (FTLD) and AD neuropathology. In addition, are there other factors of the neuropsychological assessment that can be used to enhance the accuracy of underlying pathology?

METHODS

Using a logistic regression we retrospectively compared neurocognitive performance on initial evaluation of 106 patients with pathologically verified FTLD (pvFTLD), with 558 pathologically verified AD (pvAD) patients from the National Alzheimer's Coordinating Center using data from the Uniform Data Set (UDS) and the neuropathology data set.

RESULTS

As expected, pvFTLD patients were younger, demonstrated better memory performance, and had more neuropsychiatric symptoms than pvAD patients. Other results were less predictable: pvFTLD patients performed better on one test of executive function (trail making test part B) but worse on another (digit span backward). Performance on language testing did not strongly distinguish the 2 groups. To determine what factors led to a misdiagnosis of AD in patients with FTLD, we further analyzed a small group of pvFTLD patients. These patients demonstrated older age and lower Neuropsychiatric Inventory Questionnaire counts compared with accurately diagnosed cases.

CONCLUSIONS

Other than memory, numerical scores of neurocognitive performance on the UDS are of limited value in differentiating FTLD from AD at the initial visit. These results highlight the difficulty of obtaining an accurate early diagnosis of FTLD and argue for adding supplemental tests to those included in the UDS to assess cognition in FTD and AD patients.

摘要

背景/目的:额颞叶痴呆(FTD)与阿尔茨海默病(AD)在临床队列中的认知差异已有详尽描述,但在病理验证研究中却鲜有证实。对于新兴疗法的成功而言,在疾病进程早期确定潜在病理状况愈发重要。神经心理学评估是AD和FTD诊断检查的重要组成部分。FTD患者被认为在语言和执行功能方面存在更严重缺陷,而AD患者更可能在记忆方面存在缺陷。

目的

确定初次认知测试的表现能否可靠地区分额颞叶变性(FTLD)患者和AD神经病理学患者。此外,神经心理学评估的其他因素是否可用于提高潜在病理诊断的准确性?

方法

我们采用逻辑回归,回顾性比较了106例经病理证实的FTLD(pvFTLD)患者与558例经病理证实的AD(pvAD)患者初次评估时的神经认知表现,这些AD患者来自国家阿尔茨海默病协调中心,数据来源于统一数据集(UDS)和神经病理学数据集。

结果

正如预期,pvFTLD患者比pvAD患者更年轻,记忆表现更好,且有更多神经精神症状。其他结果则较难预测:pvFTLD患者在一项执行功能测试(连线测验B部分)中表现更好,但在另一项测试(倒背数字)中表现更差。语言测试表现并不能有力地区分这两组患者。为确定哪些因素导致FTLD患者被误诊为AD,我们进一步分析了一小部分pvFTLD患者。与准确诊断的病例相比,这些患者年龄更大,神经精神症状问卷评分更低。

结论

除记忆外,UDS上神经认知表现的数值评分在初次就诊时区分FTLD和AD的价值有限。这些结果凸显了准确早期诊断FTLD的困难,并主张在UDS所包含的测试基础上增加补充测试,以评估FTD和AD患者的认知情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索